Клиническая эффективность рабепразола
Аннотация
Об авторах
Е. Ю. ПлотниковаРоссия
А. С. Сухих
Россия
Т. Ю. Грачева
Россия
Л. Г. Вологжанина
Россия
Список литературы
1. Sachs G, Chang HH, Rabon E et al. A non-electrogenic H+ pump in plasma membrane of hog stomach. J. Biol. Chem. 1976; 251: 7690-7698.
2. Parsons ME. Proton Pump Inhibitors. Gut. 2000; 47: 316.
3. Fellenius E, Berglindh T, Sachs G et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking H+, K+ATPase. Nature. 1981; 290: 156-161.
4. Olbe L, Haglund U, Leth R et al. Effect of substituted benzimidazole (H149/94) on gastric acid secretion in humans. Gastroenterology. 1982; 83: 193-198.
5. Robinson M. New-generation proton pump inhibitors: over-coming the limitations of early-generation agents. Eur. J. Gastroenterol. Hepatol. 2001; 13 (1) 6: S43-S47.
6. Luo JY, Niu CY, Wang XQ et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol. 2003; 9
7. Лопина О. Д., Сереброва С. Ю. Основные фармакокинетические характеристики ингибиторов протонного насоса и эффективность их действия. Пособие для врачей. 2016, М: ООО «Принталлогги», 40 с.
8. Fass R. Medical Management of GERD. DDW. 2002; 122: 625-632.
9. Cash B. Clinical Applications of Proton-Pump Inhibitors. American College of Gastroenterology 67th Annual Scientific Meeting.- URL: http://www.medscape. org/viewarticle/463422.
10. Paterson W. L. Improving the Management of GERD. Evidence-based therapeutic strategies, American Gastroenterological Association, Consensus Development Panel, Consensus Opinion in Gastroenterology, 2002.- URL: http://www.gastro.org/edu/ GERDmonograph.pdf.
11. Castell DO, Fennerty MB, Johnson DA, Kahrilas PJ. A critical analysis of the new PPI esomeprazole. AGA New Drug Review. 2001; September: 3-20.
12. Adachi K, Hashimoto T, Hamamoto N et al. Symptom relied in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol. 2003; 18 (12): 1392-1398.
13. Holtmann G, Bytzer P, Metz M et al. A randomized, double-blind, comparative study of standart-dose rabeprazole and high-dose omeprasole in gastro-esophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 479-485.
14. Yamano H, Yanagihara S, Matsushita H. Clinical relevance of antisecretory effect of a novel PPI, rabeprazole, in GERD patients with respect to 2C 19 genotypes. Gut. 2004; 53 (1): A106.
15. Gardner JD, Perdomo C, Sloan S et al. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 2002; 16: 455-464.
16. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 1998; 93: 763-767.
17. Williams MP, Sercombe J, Hamilton MI, Pouder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-1089.
18. Yanagihara S, Matsushita H, Yamano H. CYP 2C 19 genotype and pharmacokinetics of a novel proton pump inhibitor, rabeprazole, with respect to acid suppression in GERD patients. Gut. 2004; 53 (VI): A107.
19. Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thio-ether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 2 (44): 458-461.
20. Bensancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric of the gastric H, K-ATP-ase with extra cytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-22446.
21. Ivashkin V, TrukhmanovA, Maev I. On-demand long term management of patients suffering from non-erosive GERD with rabeprazole mg. Gut. 2004; 36 (l): A101.
22. Cloud ML, Enas N, Humphries TJ, Bassion S. The Ra-beprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophage-al reflux disease (GERD). Dig. Dis. Sci. 1998; 43: 993-1000.
23. Inamori M, Togawa J-I, Takahashi H et al. Comparisom on intragastric pH of a single dose of omeprasole or rabeprazole: Which is suitable for on-demand therapy? J. Gastroenterol. Hepatol. 2003; 18: 1034.
24. Maiti R, Jaida J, Israel PLJ, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. The Journal of Pharmacology & Pharmacotherapeutics. 2011; 2 (3): 150-157.
25. Robinson M, Cheung E, Murthy A, Jokubaitis L. Rabeprazole efficacy in erosive GERD: subgroup analyses from the future of acid suppression therapy (F.A.S.T.) trial. Am.J. Gastroenterol. 2001; 96 (1): S33-S34.
26. Thjodleifsson B, Morocutti A, Bardhan KD. A 5-year, double-blind, randomized comparison of rabeprazole and omeprazole in GORD maintenance treatment efficacy results. Gut. 2002; 50: a4-a7.
27. Старостин Б.Д. Step in-терапия при ГЭРБ. Гастроэнтерология Санкт-Петербурга. 2003; 2-3: 158 (591).
28. Dekkers CPM, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer, a European multicentre study. Aliment. Pharmacol. Ther. 1999; 13: 179-186.
29. Katz PO, Frissora C. The pharmacology and clinical relevance of proton pump inhibitors. Curr. Gastroenterol. Rep. 2002; 4: 459-462.
30. Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotics for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am.J. Gastroenterol. 1998; 93: 1909-1913.
31. Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recen t clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44 (2): 458-461.
32. Бабак О. Я. Сравнительная характеристика клинической эффективности рабепразола и других ингибиторов протонной помпы по результатам мета-анализа. Сучасна гастроентерология. 2007; 3 (35): 32-37.
33. Ng F, Lam K, Wong S et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77: 173-7.
34. Ray W, Murray K, Griffin M et al. Outcomes with concurrent use ofclopidogrel and proton-pump inhibitors: a cohort study. Ann. Intern. Med. 2010; 152: 337-45.
35. Lanas A, Garcia-Rodriguez L, Arroyo M et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.
36. Blume H, Donath F, Warnke A, Schug B. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety, Volume 29. 2006; 9 (16): 769-784.
37. Hokimoto S, Ogawa H, Yamamoto K et al. Is Impact of Proton Pump Inhibitor on Platelet Reactivity to Clopidogrel A Class Effect? Abstract 5010. Circulation. 2009; 120: S 1033.
38. Kenngott S, Olze R, Kollmer M et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur. J. Med. Res. 2010 May 18; 15 (5): 220-4.
39. Hsiao F, Mullins C, Wen Y et al. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2011 Oct; 20 (10): 1043-9.
40. Shen L, Wu F et al. Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Patients of Acute Coronary Syndrome in Taiwan. Br. J. Clin. Pharmacol. 2012 Feb 24; 74 (5): 824-834.
41. Fujishiro M, Higuchi K, Kato M, Kinoshita Y, Iwakiri R, Watanabe T, Takeuchi T, Sugisaki N, Okada Y, Ogawa H, Arakawa T, Fujimoto K. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J. Clin. Biochem. Nutr. 2015 May; 56 (3): 228-239.
42. Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev. Gastroenterology & Hepatology. 2012; 6 (4): 423-435.
Рецензия
Для цитирования:
Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г. Клиническая эффективность рабепразола. Медицинский алфавит. 2017;1(9):40-45.
For citation:
Plotnikova E.Yu., Sukhikh A.S., Grachyova T.Yu., Vologzhanina L.G. Clinical efficacy of rabeprazole. Medical alphabet. 2017;1(9):40-45. (In Russ.)